The global apheresis equipment market size is expected to reach USD 5.35 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 9.2% from 2024 to 2030. The rising demand for blood components, along with the rising incidence of diseases requiring blood transfusions such as leukemia, hemophilia, sickle cell anemia, and the growing usage of apheresis for cancer therapy, are all driving the demand.
The market is expected to grow significantly due to the rising prevalence of target diseases. The advantages of apheresis collection over whole blood collection, as well as the rising demand for plasma from biopharmaceutical companies for use in plasma fractionation, are all contributing to the industry's growth. Furthermore, the constant shortage of blood, and even the demand to ensure the safety of the blood that is provided, has shifted attention to apheresis blood.
The U.S. Federal Government has been very involved in the funding of apheresis research through its benefit programs such as Medicare, Medicaid, veterans’ health administration military, and employee insurance programs. Medicare provides coverage for apheresis regardless of whether the procedure is performed in a hospital or a blood center. In addition, private insurers have recently begun to closely examine apheresis procedures and issue policy statements pertaining to coverage.
The industry is also expected to be driven by technological innovations aimed at delivering relatively more effective and faster results. Healthcare practitioners and researchers are now in need of devices requiring minimum human intervention and the introduction of fully automatic apheresis equipment with enhanced displays is expected to improve usage rates.
The outbreak of COVID-19 had a significant impact on the market. Due to travel restrictions and social distancing, many donors refrained from blood donation leading to the cancellation of blood donation camps. The Indian Red Cross Society used to collect 200 units of blood in one day. This fell by 80% to 30-40 units in 2020. However, demand for plasma therapy during the later phase of the pandemic increased the demand for plasmapheresis.
Request a free sample copy or view the report summary: Apheresis Equipment Market Report
The disposable apheresis kits segment accounted for the largest market share of 72.17% in 2023 due to the high prevalence of blood-related disorders, extensive usage of disposable kits, and demand for apheresis procedures.
The neurology segment accounted for the largest share of 50.94% in 2023 and is expected to register the fastest CAGR from 2024 to 2030.
The plasmapheresis segment accounted for the largest share of 51.98% in 2023 due to the increasing incidence of leukemia, lymphoma, and myeloma in the U.S.
North America dominated the overall apheresis equipment market with a share of 34.99% in 2023. This is due to the high prevalence of blood-related diseases and demand for blood components.
Grand View Research has segmented the global apheresis equipment market on the basis of product, application, procedure, technology, and region:
Apheresis Equipment Product Outlook (Revenue, USD Million, 2018 - 2030)
Disposable Apheresis Kits
Devices
Apheresis Equipment Application Outlook (Revenue, USD Million, 2018 - 2030)
Renal Diseases
Hematology
Neurology
Others
Apheresis Equipment Procedure Outlook (Revenue, USD Million, 2018 - 2030)
Plasmapheresis
Photopheresis
Leukapheresis
Plateletpheresis
LDL Apheresis
Erythrocytapheresis
Others
Apheresis Equipment Technology Outlook (Revenue, USD Million, 2018 - 2030)
Membrane Filtration
Centrifugation
Apheresis Equipment Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Norway
Sweden
Denmark
Asia Pacific
China
Japan
India
Thailand
South Korea
Australia
Latin America
Mexico
Brazil
Argentina
MEA
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players of Apheresis Equipment Market
Asahi Kasei Medical Co., Ltd.
Terumo BCT, Inc. (a Part of Terumo Corporation)
Haemonetics Corporation
Fresenius Kabi AG
B. Braun SE
Mallinckrodt Plc
Nikkiso Europe GmbH (a Part of NIKKISO Group)
"The quality of research they have done for us has been excellent..."